• 1
    LeRoith D,Roberts CT,Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 12737.
  • 2
    Steele-Perkins G,Turner J,Edman JC,Hari J,Pierce SB,Stover C,Rutter WJ,Roth RA. Expression and characterization of a functional human insulin-like growth factor I receptor. J Biol Chem 1988; 263: 1148692.
  • 3
    Butler JC,Spika JS,Nichol KL,Shapiro ED,Breinan RF. Effectiveness of pneumococcal vaccine. Lancet 1998; 351: 1961.
  • 4
    Lee AV,Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995; 49: 41521.
  • 5
    Baserga R. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res 1995; 55: 24952.
  • 6
    Neuenschwander S,Roberts CT,Jr,LeRoith D. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. Endocrinology 1995; 136: 4298303.
  • 7
    Giovannucci E,Pollak MN,Platz EA,Willett WC,Stampfer MJ,Majeed N,Colditz GA,Speizer FE,Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 3459.
  • 8
    Hankinson SE,Willett WC,Colditz GA,Hunter DJ,Michaud DS,Deroo B,Rosner B,Speizer FE,Pollak M. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351: 13936.
  • 9
    Chan JM,Stampfer MJ,Giovannucci E,Gann PH,Ma J,Wilkinson P,Hennekens CH,Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 5636.
  • 10
    Sun XJ,Goldberg JL,Qiao LY,Mitchell JJ. Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 1999; 48: 135964.
  • 11
    Sun XJ,Wang LM,Zhang Y,Yenush L,Myers MG,Jr,Glasheen E,Lane WS,Pierce JH,White MF. Role of IRS-2 in insulin and cytokine signaling. Nature 1995; 377: 1737.
  • 12
    Lavan BE,Lienhard GE. The insulin-elicited 60-kDa phosphotyrosine protein in rat adipocytes is associated with phosphatidylinositol 3-kinase. J Biol Chem 1993; 268: 59218.
  • 13
    Pelicci G,Lanfrancone L,Grignani F,McGlade J,Cavallo F,Forni G,Nicoletti I,Grignani F,Pawson T,Pelicci PG. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93104.
  • 14
    Backer JM,Myers MG,Jr,Shoelson SE,Chin DJ,Sun XJ,Miralpeix M,Hu P,Margolis B,Skolnik EY,Schlessinger J. Phosphatidylinositol 3′-kinase is activated by association with IRS-1 during insulin stimulation. EMBO J 1992; 11: 346979.
  • 15
    Skolnik EY,Lee CH,Batzer A,Vicentini LM,Zhou M,Daly R,Myers MJ,Jr,Backer JM,Ullrich A,White MF. The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signaling. EMBO J 1993; 12: 192936.
  • 16
    Haglund K,Sigismund S,Polo S,Szymkiewicz I,Di Fiore PP,Dikic I. Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 2003; 5: 4616.
  • 17
    Lin FT,Daaka Y,Lefkowitz RJ. Beta-arrestins regulate mitogenic signaling and clathrin-mediated endocytosis of the insulin-like growth factor I receptor. J Biol Chem 1998; 273: 316403.
  • 18
    Biedi C,Panetta D,Segat D,Cordera R,Maggi D. Specificity of insulin-like growth factor I and insulin on Shc phosphorylation and Grb2 recruitment in caveolae. Endocrinology 2003; 144: 5497503.
  • 19
    Chow JC,Condorelli G,Smith RJ. Insulin-like growth factor-I receptor internalization regulates signaling via the Shc/mitogen-activated protein kinase pathway, but not the insulin receptor substrate-1 pathway. J Biol Chem 1998; 273: 467280.
  • 20
    Vecchione A,Marchese A,Henry P,Rotin D,Morrione A. The Grb10/Nedd4 complex regulates ligand-induced ubiquitination and stability of the insulin-like growth factor I receptor. Mol Cell Biol 2003; 23: 336372.
  • 21
    Girnita L,Girnita A,Larsson O. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Natl Acad Sci USA 2003; 100: 824752.
  • 22
    Carelli S,Di Giulio AM,Paratore S,Bosari S,Gorio A. Degradation of insulin-like growth factor-I receptor occurs via ubiquitin-proteasome pathway in human lung cancer cells. J Cell Physiol 2006; 208: 35462.
  • 23
    Sehat B,Andersson S,Vasilcanu R,Girnita L,Larsson O. Role of ubiquitination in IGF-1 receptor signaling and degradation. PLoS ONE 2007; 2: e340.
  • 24
    Girnita L,Shenoy SK,Sehat B,Vasilcanu R,Girnita A,Lefkowitz RJ,Larsson O. {beta}-Arrestin is crucial for ubiquitination and down-regulation of the insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3 ligase. J Biol Chem 2005; 280: 244129.
  • 25
    Larsson O,Girnita A,Girnita L. Role of insulin-like growth factor 1 receptor signaling in cancer. Br J Cancer 2005; 92: 2097101.
  • 26
    Bartucci M,Morelli C,Mauro L,Ando S,Surmacz E. Differential insulin-like growth factor I receptor signaling and function in estrogen receptor (ER)-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells. Cancer Res 2001; 61: 674754.
  • 27
    Burtrum D,Zhu Z,Lu D,Anderson DM,Prewett M,Pereira DS,Bassi R,Abdullah R,Hooper AT,Koo H,Jimenez X,Johnson D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand–dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63: 891221.
  • 28
    Maloney EK,McLaughlin JL,Dagdigian NE,Garrett LM,Connors KM,Zhou XM,Blattler WA,Chittenden T,Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 507383.
  • 29
    Goetsch L,Gonzalez A,Leger O,Beck A,Pauwels PJ,Haeuw JF,Corvaia N. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113: 31628.
  • 30
    Cohen BD,Baker DA,Soderstrom C,Tkalcevic G,Rossi AM,Miller PE,Tengowski MW,Wang F,Gualberto A,Beebe JS,Moyer JD. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11: 206373.
  • 31
    Pandini G,Wurch T,Akla B,Corvaia N,Belfiore A,Goetsch L. Functional responses and in vivo anti-tumor activity of h7C10: a humanized monoclonal antibody with neutralizing activity against the insulin-like growth factor-1 (IGF-1) receptor and insulin/IGF-1 hybrid receptors. Eur J Cancer 2007; 43: 131827.
  • 32
    Feng Y,Zhu Z,Xiao X,Choudhry V,Barrett JC,Dimitrov DS. Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther 2006; 5: 11420.
  • 33
    Yeh J,Litz J,Hauck P,Ludwig DL,Krystal GW. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008; 60: 16674.
  • 34
    Mitsiades CS,Mitsiades NS,McMullan CJ,Poulaki V,Shringarpure R,Akiyama M,Hideshima T,Chauhan D,Joseph M,Libermann TA,Garcia-Echeverria C,Pearson MA, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5: 22130.
  • 35
    Garcia-Echeverria C,Pearson MA,Marti A,Meyer T,Mestan J,Zimmermann J,Gao J,Brueggen J,Capraro HG,Cozens R,Evans DB,Fabbro D, et al. In vivo antitumor activity of NVP-AEW541—a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5: 2319.
  • 36
    Andrews DW,Resnicoff M,Flanders AE,Kenyon L,Curtis M,Merli G,Baserga R,Iliakis G,Aiken RD. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 2001; 19: 2189200.
  • 37
    Dupont J,Karas M,LeRoith D. The potentiation of estrogen on insulin-like growth factor I action in MCF-7 human breast cancer cells includes cell cycle components. J Biol Chem 2000; 275: 35893901.
  • 38
    Staub O,Rotin D. Role of ubiquitylation in cellular membrane transport. Physiol Rev 2006; 86: 669707.
  • 39
    Salatino M,Schillaci R,Proietti CJ,Carnevale R,Frahm I,Molinolo AA,Iribarren A,Charreau EH,Elizalde PV. Inhibition of in vivo breast cancer growth by antisense oligodeoxynucleotides to type I insulin-like growth factor receptor mRNA involves inactivation of ErbBs. PI-3K/Akt and p42/p44 MAPK signaling pathways but not modulation of progesterone receptor activity. Oncogene 2004; 23: 516174.
  • 40
    Tashiro E,Tsuchiya A,Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007; 98: 62935.
  • 41
    Dufourny B,Alblas J,van Teeffelen HA,van Schaik FM,van der BB,Steenbergh PH,Sussenbach JS. Mitogenic signaling of insulin-like growth factor I in MCF-7 human breast cancer cells requires phosphatidylinositol 3-kinase and is independent of mitogen-activated protein kinase. J Biol Chem 1997; 272: 3116371.
  • 42
    Jackson-Booth PG,Terry C,Lackey B,Lopaczynska M,Nissley P. Inhibition of the biologic response to insulin-like growth factor I in MCF-7 breast cancer cells by a new monoclonal antibody to the insulin-like growth factor-I receptor. The importance of receptor down-regulation. Horm Metab Res 2003; 35: 8506.
  • 43
    Wang Y,Hailey J,Williams D,Wang Y,Lipari P,Malkowski M,Wang X,Xie L,Li G,Saha D,Ling WL,Cannon-Carlson S, et al. Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody. Mol Cancer Ther 2005; 4: 121421.
  • 44
    Adams J,Palombella VJ,Sausville EA,Johnson J,Destree A,Lazarus DD,Maas J,Pien CS,Prakash S,Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 261522.
  • 45
    Rodgers KJ,Dean RT. Assessment of proteasome activity in cell lysates and tissue homogenates using peptide substrates. Int J Biochem Cell Biol 2003; 35: 71627.
  • 46
    Longva KE,Blystad FD,Stang E,Larsen AM,Johannessen LE,Madshus IH. Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 2002; 156: 84354.
  • 47
    Fuertes G,Martin De Llano JJ,Villarroya A,Rivett AJ,Knecht E. Changes in the proteolytic activities of proteasomes and lysosomes in human fibroblasts produced by serum withdrawal, amino-acid deprivation and confluent conditions. Biochem J 2003; 375: 7586.
  • 48
    Alwan HA,van Zoelen EJ,van Leeuwen JE. Ligand-induced lysosomal epidermal growth factor receptor (EGFR) degradation is preceded by proteasome-dependent EGFR de-ubiquitination. J Biol Chem 2003; 278: 3578190.
  • 49
    van Weert AW,Dunn KW,Gueze HJ,Maxfield FR,Stoorvogel W. Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump. J Cell Biol 1995; 130: 82134.
  • 50
    van Deurs B,Holm PK,Sandvig K. Inhibition of the vacuolar H(+)-ATPase with bafilomycin reduces delivery of internalized molecules from mature multivesicular endosomes to lysosomes in HEp-2 cells. Eur J Cell Biol 1996; 69: 34350.
  • 51
    Clague MJ,Urbe S,Aniento F,Gruenberg J. Vacuolar ATPase activity is required for endosomal carrier vesicle formation. J Biol Chem 1994; 269: 214.
  • 52
    Hailey J,Maxwell E,Koukouras K,Bishop WR,Pachter JA,Wang Y. Neutralizing anti-insulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther 2002; 1: 134953.
  • 53
    Sehat B,Andersson S,Girnita L,Larsson O. Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis. Cancer Res 2008; 68: 566977.
  • 54
    Baserga R,Peruzzi F,Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107: 8737.